Company: AZN
Filing Date: 2025-12-16
Form Type: 6-K
Source: 0001654954-25-013974
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-12-16
Form: 6-K
Chunk 6
---
9;1(4):e208-e219.

15. Furie R, et al. Anifrolumab, an anti-interferon ‐ a receptor monoclonal antibody, in moderate ‐ to ‐ severe systemic lupus erythematosus. Arthritis Rheumatol . 2017;69(2):376-386.

16. AstraZeneca data on file. 2025. REF-290598.

17. Murimi-Worstell IB, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open . 2020;10:e031850.

18. Katsumata Y et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis . 2024;83:998-1005.

19. Clinicaltrials.gov Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip-SC). Available at: https://clinicaltrials.gov/study/NCT04877691 . [Last accessed: December 2025].

20. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med . 2018;5(1):e000261.

21. Lauwerys BR, et al. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology . 2014;53(8):1369-1376.

22. Sarkar MK, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis . 2018;77(11):1653-1664.

23. Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol . 2019;10:325.

24. Mai L, et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther . 2021;23(1):29.

25. López de Padilla CM, et al. The type I interferons